Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy And Safety Trial Of Sublingual-Oral Immunotherapy (SLIT) In Adults With Allergic Rhinoconjunctivitis Caused By Ragweed Pollen

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy And Safety Trial Of Sublingual-Oral Immunotherapy (SLIT) In Adults With Allergic Rhinoconjunctivitis Caused By Ragweed Pollen

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2015

At a glance

  • Drugs Ragweed allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis; Asthma; Ragweed pollen hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Dec 2013 Results published in the Journal of Allergy and Clinical Immunology.
    • 26 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 12 Jun 2012 Primary endpoint 'Symptom-score' has been met, according to a Greer Laboratories media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top